Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

ClinicalTrials.gov ID: NCT07843459

Public ClinicalTrials.gov record NCT07843459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.

Study identification

NCT ID
NCT07843459
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
111 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2026 (Estimated)
Primary completion
Jul 2028 (Estimated)
Completion
Jul 2028 (Estimated)
Last update posted
Sep 28, 2026

2026 – 2028

United States locations

U.S. sites
13
U.S. states
4
U.S. cities
13
Facility City State ZIP Site status
CenExel ACT Anaheim California 92801 —
Irvine Clinical Research Irvine California 92614 —
Collaborative Neuroscience Network - CNS Los Alamitos California 90720 —
Fortrea Clinical Research Unit Daytona Beach Florida 32117 —
K2 Medical Research - The Villages Lady Lake Florida 32159 —
K2 Medical Research Maitland Florida 32751 —
Charter Research Orlando Florida 32803 —
Progressive Medical Research Port Orange Florida 32127 —
Alzheimer's Research and Treatment Center Stuart Florida 34996 —
K2 Medical Research - Tampa Tampa Florida 33634 —
Charter Research The Villages Florida 32162-2698 —
Accel Research Sites - NeuroStudies Clinical Research Unit Decatur Georgia 30030 —
QUEST Research Institute Farmington Hills Michigan 48334 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07843459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 28, 2026 · Synced Oct 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07843459 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →